Home / Catalogue/ Longevity/ FOXO4-DRI

LongevityIn StockSubQ injection

FOXO4-DRI

D-retro-inverso peptide · FOXO4-p53 interface · Synthetic

Half-life

~6-12h

After administration

Delivery Method

SubQ injection

Route of administration

Storage (Lyophilised)

12-24 months

2–8°C

Storage (Reconstituted)

2–4 weeks

Refrigerate at 2-8C

Known For

Senolytic peptide. Selectively causes senescent ('zombie') cells to undergo apoptosis (self-destruct). These accumulated senescent cells drive aging and inflammation. Potentially one of the most powerful anti-aging interventions available.

Mechanism of Action

⚠️ HIGHLY EXPERIMENTAL. Disrupts FOXO4-p53 interaction → triggers senescent cell apoptosis (programmed death). "Senolytic peptide" — clears zombie cells.

Body vs. External Supply

🔴 Exogenous (replaces natural)

Brand / Trade Names

No pharmaceutical brand ⚠️ Research compound only Extremely expensive No commercial development

Typical Research Dosage

Highly experimental. Published mouse dosing: 5mg/kg. Human protocols vary widely: 5-20mg per session, intermittent dosing (e.g., 3 days on, 2 weeks off). No established human protocol.

Vial Duration Guide

10mg vial = 1-2 sessions at most. Very expensive compound.

Recommended Vial Size

★ 10mg (only size) Intermittent dosing (3 days on, 2 weeks off). ~1 vial per session. Used quickly. No shelf life concern.

Time to Effects

EARLY: Unknown FULL: Unknown ⚠️ HIGHLY EXPERIMENTAL. No established human timelines. Animal studies showed senescent cell clearance within 2-3 weeks of treatment. Effects manifested as improved coat quality, activity levels, and organ function in aged mice. Human anecdotal reports (very limited): improved energy, skin quality, and 'youthful feeling' within weeks of a course. No validated human timeline exists. Effects are measured in biomarkers of aging, not immediate subjective feelings.

Contraindications & Do Not Combine

• ⚠️ Highly experimental — avoid combining with other senolytics (Fisetin, Dasatinib+Quercetin) until safety is better understood • Unknown interaction profile with most compounds

Common Side Effects

⚠️ COMPLETELY UNKNOWN IN HUMANS. Mouse data: transient weight loss, fur regrowth, fitness improvement in aged mice.

Drug Interactions

Unknown — no human pharmacology data

Reversibility

Unknown — senescent cell clearance is presumably permanent (cleared cells don't come back). But consequences of clearing senescent cells in humans are UNKNOWN.

Key Peer-Reviewed References

All studies are published in indexed journals unless otherwise noted.

• Baar et al. (2017) Cell 169:132-47 — Targeted senescent cell clearance in aged mice • Published in Cell — high-impact journal • NO HUMAN TRIALS conducted • NOT FDA APPROVED • ⚠️ HIGHLY EXPERIMENTAL — only mouse data exists • Extremely expensive; complex D-retro-inverso peptide

Research Disclaimer

Almost all data is preclinical (animal or in-vitro). No large-scale randomised controlled human trials are available for most compounds on this catalogue. This information is provided for research reference only.

Storage Requirements

Research: -20°C to -80°C (very unstable). 2-8°C short-term.

State	Condition	Duration
Lyophilised (sealed)	2–8°C	12-24 months
Reconstituted	2-8C	2–4 weeks

Reconstitution Note

Reconstitute with bacteriostatic water (BAC water). Do not shake vigorously -- swirl gently to dissolve. Inject BAC water slowly down the side of the vial to avoid denaturing the peptide.

Video Resources

FOXO4-DRI discussed by researchers & practitioners

Independent educational content from researchers, clinicians, and science communicators. Not affiliated with Pepnerd — provided as supplementary reading.

Educational resources only. The videos above are independent third-party content from researchers, clinicians, and science communicators. Pepnerd is not affiliated with any of these creators and does not endorse or make any claims based on their content. All products are sold strictly for in-vitro scientific research.

Select Vial Size

$375.00 per vial

Submit Your Test Results →

Quick Reference

Half-life	D-amino acid composition makes FOXO4-DRI highly resistant to proteolysis; estimated plasma half-life ~6-12h based on daily dosing protocols
Delivery	SubQ injection
Typical dose	5mg
Storage (lyoph.)	2–8°C
Storage (recon.)	2–4 weeks
Endogenous?	Exogenous (replaces natural)
Suppression	None known
WADA	Not listed — investigational
FDA status	Preclinical only